Patents by Inventor Jogeshwar Mukherjee
Jogeshwar Mukherjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11679103Abstract: The disclosure provides for multi-targeting agents that assist in the targeted removal of amyloid beta plaques from the brain and surrounding vasculature of subjects with Alzheimer's disease, and methods of treatment thereof.Type: GrantFiled: November 27, 2019Date of Patent: June 20, 2023Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Aparna Baranwal, Heather Ho, Gurleen Samra, Kenneth Dang, Megan Rose Felix
-
Publication number: 20220008563Abstract: The disclosure provides compounds for detecting neurodegeneration and/or identifying and monitoring the progression of inflammation in neurodegenerative diseases. The disclosure further provides compounds that inhibit the activity of monoamine oxidases, and uses thereof.Type: ApplicationFiled: July 9, 2021Publication date: January 13, 2022Inventors: Jogeshwar Mukherjee, Christopher Liang, Phuc Quang Lam, Rommani Mondal, Stephanie Martinez
-
Publication number: 20200171016Abstract: The disclosure provides for multi-targeting agents that assist in the targeted removal of amyloid beta plaques from the brain and surrounding vasculature of subject's with Alzheimer's disease, and methods of treatment thereof.Type: ApplicationFiled: November 27, 2019Publication date: June 4, 2020Inventors: Jogeshwar Mukherjee, Aparna Baranwal, Heather Ho, Gurleen Samra, Kenneth Dang, Megan Rose Felix
-
Patent number: 9662059Abstract: The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes and related to monitor disease progression or treatment efficacy of candidate drugs.Type: GrantFiled: April 25, 2008Date of Patent: May 30, 2017Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, George Chandy, Norah Milne, Ping H. Wang, Balu Easwaramoorthy, Joseph Mantil, Adriana Garcia
-
Patent number: 9546193Abstract: Various compositions and methods for Quasi-Amadori products and derivatives thereof are contemplated in which a halogenated carbohydrate is reacted with a primary amino group of an affinity ligand. In especially preferred aspects, the Quasi-Amadori product is formed from 2-fluorodeoxyglucose and an affinity moiety that preferentially or selectively binds to a neural cell or neural structure. Where contemplated compounds include 18F, PET imaging using compounds presented herein is especially preferred.Type: GrantFiled: October 24, 2014Date of Patent: January 17, 2017Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Aparna Baranwal, Nehal Mahendra Shah
-
Patent number: 9180212Abstract: Various compounds, compositions, and methods for binding to ?-amyloid plaque and norepinephrine transporters are presented. Especially preferred compounds include those with a PET-detectable label.Type: GrantFiled: May 22, 2013Date of Patent: November 10, 2015Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Min-Liang Pan
-
Publication number: 20150291647Abstract: Various compositions and methods for Quasi-Amadori products and derivatives thereof are contemplated in which a halogenated carbohydrate is reacted with a primary amino group of an affinity ligand. In especially preferred aspects, the Quasi-Amadori product is formed from 2-fluorodeoxyglucose and an affinity moiety that preferentially or selectively binds to a neural cell or neural structure. Where contemplated compounds include 18F, PET imaging using compounds presented herein is especially preferred.Type: ApplicationFiled: October 24, 2014Publication date: October 15, 2015Inventors: Jogeshwar Mukherjee, Aparna Baranwal, Nehal Mahendra Shah
-
Patent number: 9029557Abstract: Contemplated compositions and methods are employed to bind in vitro and in vivo to an ?4?2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with ?4?2 dysfunction.Type: GrantFiled: February 6, 2013Date of Patent: May 12, 2015Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Sharon A. Kuruvilla
-
Publication number: 20140050663Abstract: Contemplated compositions and methods are employed to bind in vitro and in vivo to an ?4?2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with ?4?2 dysfunction.Type: ApplicationFiled: February 6, 2013Publication date: February 20, 2014Applicant: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Sharon A. Kuruvilla
-
Publication number: 20130315826Abstract: Various compounds, compositions, and methods for binding to ?-amyloid plaque and norepinephrine transporters are presented. Especially preferred compounds include those with a PET-detectable label.Type: ApplicationFiled: May 22, 2013Publication date: November 28, 2013Applicant: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Min-Liang Pan
-
Patent number: 8378109Abstract: Contemplated compositions and methods are employed to bind in vitro and in vivo to an ?4?2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with ?4??2 dysfunction.Type: GrantFiled: December 1, 2005Date of Patent: February 19, 2013Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Ramaiah Pichika, Steven Potkin, Frances Leslie, Sankha Chattopadhyay
-
Patent number: 7737183Abstract: Compounds, compositions and methods are contemplated in which senile plaques and/or neurofibrillary tangles are labeled using compounds with improved permeability across the blood brain barrier and improved selective binding to senile plaques and/or neurofibrillary tangles. Contemplated compounds are derivatives of FDDNP or curcumin, which most preferably have improved solubility in aqueous solvents. Labeling is typically performed using a PET detectable label, and especially 11C and 18F.Type: GrantFiled: October 17, 2007Date of Patent: June 15, 2010Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Elizabeth Head, Crystal Wang, Pooja C. Patel
-
Patent number: 7731940Abstract: Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with 18F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.Type: GrantFiled: January 24, 2007Date of Patent: June 8, 2010Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Neil Saigal
-
Publication number: 20090297443Abstract: Contemplated compositions and methods are employed to bind in vitro and in vivo to an ?4?2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with ?4??2 dysfunction.Type: ApplicationFiled: December 1, 2005Publication date: December 3, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jogeshwar Mukherjee, Ramaiah Pichika, Steven Potkin, Frances Leslie, Sankha Chattopadhyay
-
Publication number: 20090004107Abstract: Compounds, compositions and methods are contemplated in which senile plaques and/or neurofibrillary tangles are labeled using compounds with improved permeability across the blood brain barrier and improved selective binding to senile plaques and/or neurofibrillary tangles. Contemplated compounds are derivatives of FDDNP or curcumin, which most preferably have improved solubility in aqueous solvents. Labeling is typically performed using a PET detectable label, and especially 11C and 18F.Type: ApplicationFiled: October 17, 2007Publication date: January 1, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jogeshwar Mukherjee, Elizabeth Head, Crystal Wang, Pooja C. Patel
-
Publication number: 20080319310Abstract: The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes and related to monitor disease progression or treatment efficacy of candidate drugs.Type: ApplicationFiled: April 25, 2008Publication date: December 25, 2008Inventors: Jogeshwar Mukherjee, George Chandy, Norah Milne, Ping H. Wang, Balu Easwaramoorthy, Joseph Mantil
-
Publication number: 20070196271Abstract: Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with 18F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.Type: ApplicationFiled: January 24, 2007Publication date: August 23, 2007Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jogeshwar Mukherjee, Neil Saigal
-
Patent number: RE43688Abstract: Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with 18F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.Type: GrantFiled: July 21, 2011Date of Patent: September 25, 2012Assignee: The Regents of the University of CaliforniaInventors: Jogeshwar Mukherjee, Neil Saigal, Harsh Saigal, legal representative